SCHEMBL25818614

SCHEMBL25818614

COC(=O)C1CCN(c2cc(C#N)ccn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
MALT1 Q9UDY8 1/20 0.58
HRH3 Q9Y5N1 1/20 0.57
CHRM4 P08173 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PANK3 Q9H999 1/20 0.51
KCNMA1 Q12791 1/20 0.51
THRB P10828 1/20 0.50
USP30 Q70CQ3 1/20 0.48
LMNA P02545 1/20 0.48
CCR2 P41597 1/20 0.47
TP53 P04637 1/20 0.47
CNR2 P34972 1/20 0.46
HCRTR1 O43613 3/20 0.45
HCRTR2 O43614 3/20 0.45
TACR3 P29371 3/20 0.44
ADORA3 P0DMS8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339003 0.95 MALT1 (0.54) KDM4EMALT1HRH3CHRM4MEN1
Trifluoroacetic Acid SCHEMBL30338667 0.90 MALT1 (0.52) KDM4EMALT1HRH3CHRM4MEN1
SCHEMBL1990732 0.85 MALT1 (0.59) KDM4EMALT1HRH3CHRM4PANK3
SCHEMBL25245322 0.82 KDM4E (0.64) KDM4EMALT1HRH3MEN1KMT2A
SCHEMBL22533443 0.82 KDM4E (0.64) KDM4ECHRM4MEN1KMT2ASMN1; SMN2
SCHEMBL5220987 0.81 USP30 (0.57) MALT1HRH3CHRM4PANK3THRB
SCHEMBL22686737 0.81 USP30 (0.56) MALT1HRH3CHRM4PANK3THRB
SCHEMBL30547524 0.79 KDM4E (0.60) KDM4EHRH3MEN1KMT2ASMN1; SMN2
SCHEMBL25816553 0.79 KDM4E (0.60) KDM4EHRH3MEN1KMT2ASMN1; SMN2
SCHEMBL15014494 0.79 HRH3 (0.54) MALT1HRH3CHRM4PANK3THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
EP-4157835-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 KDM4E 2270/4885MALT1 813/4885HRH3 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.